Pivotal Response Treatment Package for Young Children With Autism
NCT ID: NCT02037022
Last Updated: 2020-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2013-12-04
2017-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT01988623
Treatment Efficacy for Developmental Motor Speech Disorders
NCT02105402
Interventions for Communication in Autism Network
NCT01018407
How Simplified Language Affects Comprehension and Learning in Young Autistic Children
NCT05707923
Training Early Social Language in Autism
NCT03427138
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pivotal Response Treatment Package
Pivotal Response Treatment Package (PRT-P)
Pivotal Response Treatment Package (PRT-P)
Delayed Treatment Group
Delayed Treatment Group (DTG)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pivotal Response Treatment Package (PRT-P)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females in good medical health between 2.0 and 5.11 years
* Ability to participate in the testing procedures to the extent that valid standard scores can be obtained
* Language delay as measured by the Preschool Language Scale: Standard score at least 1 Standard Deviation below average for expressive language ability
* Stable treatment, speech therapy, school placement, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation
* No more than 60 minutes of individual 1:1 speech therapy per week
* Availability of at least one parent who can consistently participate in parent training and research measures
* Parents intend on continuing Pivotal Response Treatment Package (PRT-P) for a minimum of 12 weeks
* Parents must be 18 years of age or older
Exclusion Criteria
* Receiving in-home Applied Behavior Analysis (ABA) of 10 hours or more
* A genetic abnormality, such as Fragile X
* Presence of active medical problem, such as unstable seizure disorder or heart disease
* Previous adequate PRT trial
* Participants living more than 50 miles from Stanford University
* At least one room of the house must be available to be dedicated to treatment during session times
* There must be no serious health and safety risks present in the home environment
* The research team has the right to refuse to perform sessions in-home even if the criteria above are met
2 Years
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antonio Hardan
Professor of Psychiatry and Behavioral Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonio Hardan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gengoux GW, Abrams DA, Schuck R, Millan ME, Libove R, Ardel CM, Phillips JM, Fox M, Frazier TW, Hardan AY. A Pivotal Response Treatment Package for Children With Autism Spectrum Disorder: An RCT. Pediatrics. 2019 Sep;144(3):e20190178. doi: 10.1542/peds.2019-0178. Epub 2019 Aug 6.
Gengoux GW, Schapp S, Burton S, Ardel CM, Libove RA, Baldi G, Berquist KL, Phillips JM, Hardan AY. Effects of a parent-implemented Developmental Reciprocity Treatment Program for children with autism spectrum disorder. Autism. 2019 Apr;23(3):713-725. doi: 10.1177/1362361318775538. Epub 2018 May 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-28314
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.